BIRC5/survivin was expressed at higher levels in the ER-negative tumors in all three cohorts (Figure 3B, VGR-BC p = 0.021, SCAN-B, and METABRIC p < 0.0001). This evidence concerns the gene BIRC5 and breast cancer.